Table 1.
Populations-based studies on trends in relative survival in multiple myeloma
| Reference | Study period |
Survival trend1 | Note |
|---|---|---|---|
| Kristinsson 2007 | 1973–2003 | 5-year rel survival from 31 % to 36 %. Improvement only inpatients 60 years or younger | Swedish Cancer Registry |
| Brenner 2008 | 1990–2004 | 5-year relative survival from 28.8% to 34.7%. Improvement mainly in patients 60 years or younger | SEER database |
| Waxman 2010 | 1973–2005 | 5-year rel survival from 26.3% to 35.0% in whites. No significant improvement in blacks. | SEER database |
| Turesson 2010 | 1960–2005 | Median OS from 24.3 to 56.3 months in patients 65 years or younger. No significant change in those 66 years or older | Information on treatment in individual patients City of Malmö Sweden |
| Renshaw 2010 | 1990–2004 | 5-year relative survival from 36 % to 47% in men and from 40 % to 56% in women. | Thames Cancer Registry database UK |
| Shaapveld 2010 | 1989–2005 | 5-year relative survival from 34 % to 56% in patients < 65 years. No improvement in those 66 years or older. | Two regional cancer centers the Netherlands |
| Pulte 2011 | 1973–2007 | 5-year relative survival from 32.8% to 40.3%. 10-year relative survival from 6.4% to 8.4% in patients 75 year or older | SEER database |
| Pozzi 2013 | 1988–2009 | 5-year relative survival increased from 45.7% to 55.7 %. No significant improvement in patients > 75 years | Modena Cancer Registry |
| Sant 2014 | 1997–2008 | 5-year relative survival increased from 29.8 % to 39.6 %. No significant improvement in patients > 75 years | EUROCARE-5 database |
| Kristinsson 2014 | 1973–2009 | 5-year myeloma-specific survival from 36% to 68 % in patients 50 years or younger, from 34% to 58% in age cohort 51–65, from 26% to 41 % in age cohort 66–79. | Disease-specific survival SEER database |
| Pulte 2015 | 2002–2010 | 5-year relative survival from 47.3% to 53.8% (Germany) and from 39.8% to 54,2% (US) | Patients 75 years or older excluded SEER database and Germany |
| Rios-Tamayos 2015 | 1985–2009 | Median OS from 17.7 months to 34 months. Improvement restricted to younger patients. | Granada Cancer Registry Spain |
| Chihara 2015 | 1993–2006 | No change in 5-year relative survival – from 30.0% to 27.8 %. | 6 prefectures in Japan covering 13.4% of the Japanese population. Thalidomide, bortezomib and lenalidomide not approved during the study period. |
| Jansen 2015 | 2002–2010 | 5-year relative survival increased from 39,9% to 47,9 % | 11 population-based cancer registries in Germany |
| Costa 2017 | 1993–2012 | 5-year relative survival from 36.3% to 61.8% in patients < 65 years, from 29.0% to 48.5% in age cohort 65–74 years and from 21.1% to 34.0% in age cohort 75 years or older. | SEER database |
| Blimark 2017 | 2008–2014 | 5-year relative survival increased from 47.3 % to 51.3 % | Swedish Myeloma Registry |
| Thorsteinsdottir 2018 | 1973–2013 | 5-year relative survival increased from 28% to 41% | Swedish Cancer Registry |
1
Comparison of survival for patients diagnosed in the first vs the last calendar period in each study.
2
Two studies that reported observed survival and one study reporting myeloma-specific survival included.